Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VTD versus PAD plus stem cell transplantation in newly diagnosed transplant-eligible multiple myeloma
ChiCTR1900021382Phase 3Not yet recruiting
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
- Start
- Mar 2019
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of bortezomib, thalidomide, dexamethasone and doxorubicin in multiple myeloma (MM) (2 arms), sponsored by Tianjin Medical University Cancer Institute and Hospital. Primary endpoint: Very good partial response rate. Planned start Mar 2019; status: not yet recruiting.
02
Drugs
bortezomibthalidomidedexamethasonedoxorubicin
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on ChiCTR1900021382.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1900021382.